Year Founded
2016
Ownership
Private
Employees
~50
Therapeutic Areas
NeurologyPsychiatry
Stage
Preclinical
Modalities
Small molecule

Epiodyne General Information

Lead candidate EPD-2520 demonstrated analgesia equal to oxycodone with minimal respiratory depression and reduced addiction potential in preclinical studies. Also showed potential for treating opioid dependency with reduced withdrawal effects compared to buprenorphine.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Francisco, CA
United States

Drug Pipeline

EPD-2520
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Epiodyne's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Epiodyne Funding

Deal TypeDateAmountStatusStage
Later Stage VCApr 23, 2019$8.0MCompletedPreclinical
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Epiodyne's complete valuation and funding history, request access »

Epiodyne Investors

Waycross Capital
Investor Type: Venture Capital
Holding: Minority
Mission Bay Capital
Investor Type: Venture Capital
Holding: Minority
Menlo Ventures
Investor Type: Venture Capital
Holding: Minority